Managing hereditary ovarian cancer risk

被引:0
|
作者
Berchuck, A
Schildkraut, JM
Marks, JR
Futreal, PA
机构
[1] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA
关键词
BRCA1; BRCA2; oophorectomy; ovarian cancer;
D O I
10.1002/(SICI)1097-0142(19991015)86:8+<1697::AID-CNCR8>3.0.CO;2-W
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer is the fourth leading cause of cancer deaths in American women. About 10% of cases are thought to have a hereditary basis, and family history is the strongest known risk factor. In the past, prophylactic oophorectomy has been advocated for women with two or more affected first-degree relatives. More recently, with the identification of the genes responsible for most hereditary ovarian cancers (BRCA1, BRCA2), oophorectomy can now be offered specifically to women who are mutation carriers. Conversely, noncarriers in these families can be reassured that their risk of ovarian cancer is not increased. The value of oophorectomy in mutation carriers has not yet been proven, however, and concern exists that the benefit may be less than intuitively expected. First, although the lifetime risk of ovarian cancer initially was reported to be as high as 60%, more recent studies have suggested risks in the range of 15 to 30%. A better understanding of the factors that underlie variable penetrance in mutation carriers is needed to augment our ability to counsel individual women. In addition, peritoneal papillary serous carcinoma indistinguishable from ovarian cancer occurs in some women after oophorectomy. Studies that better define the frequency with which this occurs are needed to establish the magnitude of the protective effect conferred by prophylactic oophorectomy. In view of the uncertainty regarding the efficacy of prophylactic oophorectomy, chemopreventive and early detection approaches also deserve consideration as strategies for decreasing ovarian cancer mortality in women who carry mutations in ovarian cancer susceptibility genes. (C) 1999 American Cancer Society.
引用
收藏
页码:1697 / 1704
页数:8
相关论文
共 50 条
  • [1] Managing hereditary ovarian cancer risk
    Berchuck, A
    Schildkraut, JM
    Marks, JR
    Futreal, PA
    [J]. CANCER, 1999, 86 (11) : 2517 - 2524
  • [2] Identifying and managing hereditary risk of breast and ovarian cancer
    Frank, TS
    Critchfield, GC
    [J]. CLINICS IN PERINATOLOGY, 2001, 28 (02) : 395 - +
  • [3] Managing hereditary ovarian cancer
    Mourits, M. J.
    de Bock, G. H.
    [J]. MATURITAS, 2009, 64 (03) : 172 - 176
  • [4] Managing hereditary breast cancer risk in women with and without ovarian cancer
    Peters, Mary Linton
    Garber, Judy E.
    Tung, Nadine
    [J]. GYNECOLOGIC ONCOLOGY, 2017, 146 (01) : 205 - 214
  • [5] Negotiating present and future selves: managing the risk of hereditary ovarian cancer by prophylactic surgery
    Hallowell, N
    Lawton, J
    [J]. HEALTH, 2002, 6 (04): : 423 - 443
  • [6] Misperceptions of ovarian cancer risk in women at increased risk for hereditary ovarian cancer
    Bettina Meiser
    Melanie A. Price
    Phyllis N. Butow
    Belinda Rahman
    Kathy Tucker
    Benjamin Cheah
    Adrian Bickerstaffe
    John Hopper
    Kelly-Anne Phillips
    [J]. Familial Cancer, 2014, 13 : 153 - 162
  • [7] Hereditary Ovarian Cancer and Risk Reduction
    Andrews, Lesley
    Mutch, David G.
    [J]. BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2017, 41 : 31 - 48
  • [8] Misperceptions of ovarian cancer risk in women at increased risk for hereditary ovarian cancer
    Meiser, Bettina
    Price, Melanie A.
    Butow, Phyllis N.
    Rahman, Belinda
    Tucker, Kathy
    Cheah, Benjamin
    Bickerstaffe, Adrian
    Hopper, John
    Phillips, Kelly-Anne
    [J]. FAMILIAL CANCER, 2014, 13 (02) : 153 - 162
  • [9] ACOG Guidelines for Managing Hereditary Breast and Ovarian Cancer Syndrome
    Lambert, Mara
    [J]. AMERICAN FAMILY PHYSICIAN, 2009, 80 (12) : 1505 - 1507
  • [10] Oral contraceptives and the risk of hereditary ovarian cancer
    Narod, SA
    Risch, H
    Moslehi, R
    Dorum, A
    Neuhausen, S
    Olsson, H
    Provencher, D
    Radice, P
    Evans, G
    Bishop, S
    Brunet, JS
    Ponder, BAJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (07): : 424 - 428